Andrew W. Dick

Jul 12, 2024 | ajmc.com | Kun Li |Annie Chen |Kimberley H Geissler |Andrew W. Dick |Ashley M. Kranz

ABSTRACTObjectives: To identify factors associated with clinicians’ likelihood and intensity of applying fluoride varnish (FV) overall and for visits paid by Medicaid and private insurers. Study Design: Observational study using claims data. Methods: Using the Massachusetts All-Payer Claims Database (2016-2018), we conducted a repeated cross-sectional study of 2911 clinicians (7277 clinician-year observations) providing well-child visits to children aged 1 to 5 years.

May 20, 2024 | rand.org | Megan S. Schuler |Andrew W. Dick |Adam Gordon |Brendan Saloner

BackgroundWe examined the number and characteristics of high-volume buprenorphine prescribers and the nature of their buprenorphine prescribing from 2009 to 2018. MethodsIn this observational cohort study, IQVIA Real World retail pharmacy claims data were used to characterize trends in high-volume buprenorphine prescribers (clinicians with a mean of 30 or more active patients in every month that they were an active prescriber) during 2009–2018.

Feb 5, 2024 | rand.org | Annie Chen |Isaac M. Opper |Andrew W. Dick |Bradley D. Stein

ObjectivesIn 2008, Florida's Medicaid program began reimbursing medical providers for preventive oral health services (POHS) delivered to children aged 6 months to 42 months. We examine whether Medicaid comprehensive managed care (CMC) and fee for service (FFS) had different rates of POHS during pediatric medical visits. Study DesignObservational study using claims data (2009-2012).

Jul 14, 2023 | rand.org | Megan S. Schuler |Brendan Saloner |Adam Gordon |Andrew W. Dick

Background Buprenorphine is a key medication to treat opioid use disorder (OUD). Since its approval in 2002, buprenorphine access has grown markedly, spurred by major federal and state policy changes. This study characterizes buprenorphine treatment episodes during 2007 to 2018 with respect to payer, provider specialty, and patient demographics.